|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
NRAS mutations are the most common alterations among RAS isoforms in cutaneous melanoma, with patients harboring these aggressive tumors having a poor prognosis and low survival rate.
|
31549767 |
2020 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Accordingly, in a cohort of 79 BRAF/NRAS double wild type cutaneous melanoma and 17 mucosal melanoma KIT mutation was assessed by Sanger sequencing of exons 9,11,13,17 and 18.
|
31848942 |
2020 |
|
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma.
|
31464610 |
2019 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Because the Mitogen-Activated Protein Kinase (MAPK) pathway plays such a significant role in melanoma development, we explore v-raf murine sarcoma viral oncogene homolog B (<i>BRAF)</i> and neuroblastoma RAS viral oncogene homolog (<i>NRAS)</i> mutations in mucosal melanoma and compare them to the mutation profiles in cutaneous melanoma and other tumors with <i>BRAF</i> and <i>NRAS</i> mutations.
|
31398831 |
2019 |
|
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma.
|
31391014 |
2019 |
|
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mutational status of NRAS is required in several types of cancer like colorectal or cutaneous melanoma.
|
29101736 |
2019 |
|
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Only mutations confirmed via digital droplet PCR or in BRAF, KIT and NRAS, the most frequently altered cancer genes in cutaneous melanoma, were considered as positive.
|
28191690 |
2017 |
|
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Few studies have focused on the transcriptional level of RAS isoforms (KRAS, NRAS, and HRAS) in cutaneous melanoma.
|
29349077 |
2017 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic mutations in c-KIT, NRAS and BRAF components of the MAPK pathway have been identified in nearly 90% of cutaneous melanoma and this information has been used to develop small molecules that inhibit their activity.
|
29061773 |
2017 |
|
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Management strategies are proposed for presentation of suspected melanoma of the skin and the central nervous system in patients with CMN, including use of oral mitogen-activated protein kinase kinase inhibitors in NRAS-mutated tumours.
|
28078671 |
2017 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this work we present an intensively pigmented and well-characterized cell line derived from a highly aggressive NRAS mutated cutaneous melanoma, named MUG-Mel2.
|
28522871 |
2017 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Hotspot mutations of the oncogenes BRAF and NRAS are the most common genetic alterations in cutaneous melanoma.
|
28797232 |
2017 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Activating mutations in neuroblastoma RAS viral oncogene homolog (NRAS) are frequent driver events in cutaneous melanoma.
|
26967478 |
2016 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Notably, common BRAF and NRAS mutations in cutaneous melanoma are associated with increased miR-21 expression.
|
26116372 |
2015 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
|
24749938 |
2014 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations.
|
23096702 |
2013 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
When NRAS(G12D) was expressed in the melanocytes of developing embryos, it induced melanocyte proliferation and congenital melanocytic lesions reminiscent of human blue nevi but did not induce cutaneous melanoma.
|
23303902 |
2013 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
|
21615881 |
2011 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
|
21166657 |
2011 |
|
Cutaneous Melanoma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma.
|
20703244 |
2010 |
|
Cutaneous Melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma.
|
19037234 |
2009 |
|
Cutaneous Melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The BRAF/NRAS mutation status and expression of COX-2 and iNOS were examined to compare their prognostic value for overall survival (OS) in stage III malignant cutaneous melanoma.
|
19039588 |
2009 |
|
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.
|
18227705 |
2008 |
|
Cutaneous Melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Occurrence of ocular melanoma thirteen years after skin melanoma: two separate primaries or metastatic disease? A case solved with NRAS and CDKN2A (INK4A-ARF) mutational analysis.
|
18205010 |
2008 |